Newron Pharmaceuticals SpA (NWRN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Newron Pharmaceuticals SpA (NWRN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10159
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イタリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Newron Pharmaceuticals SpA (Newron) is a research-based biopharmaceutical company which focuses on the discovery, development and commercialization of novel therapeutic drugs for the treatment of central nervous system disorders and pain. The company’s marketed product, Xadago (safinamide), is developed as an adjunctive therapy for any stage of Parkinson’s disease. Newron’s other products in pipeline include ralfinamide for neuropathic pain; sarizotan for Rett syndrome; and Evenamide (NW-3509) for the treatment of schizophrenia. The company has development and commercialization collaborations with Zambon and Meiji Seika Pharma Co., Ltd. It operates along with its subsidiaries in the UK, Sweden, Switzerland and the US. Newron is headquartered in Bresso, Milan, Italy.

Newron Pharmaceuticals SpA (NWRN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Newron Pharma Enters Into Co-Development Agreement With Zambon 11
Licensing Agreements 12
Newron Pharma Enters Into Licensing Agreement With Zambon For Safinamide 12
Newron Enters Into Licensing Agreement With Meiji Seika Pharma For Safinamide 14
Equity Offering 16
Newron Pharma Raises USD27.8 Million in Private Placement of Shares 16
Newron Pharma to Raise USD26.7 Million in Private Placement of Shares 17
Newron Pharma to Raise USD5.3 Million in Private Placement of Shares 18
Newron Pharma to Raise USD25.6 Million in Private Placement of Shares 19
Newron Pharma to Raise Funds through Public Offering of Shares 21
Newron Pharma Announces Private Placement Of Shares For US$21 Million 22
Newron Pharma Completes Private Placement Of Shares For US$4.8 Million 24
Acquisition 25
Newron Pharma Completes Acquisition Of NeuroNova For US$12 Million 25
Newron Pharmaceuticals SpA – Key Competitors 27
Newron Pharmaceuticals SpA – Key Employees 28
Newron Pharmaceuticals SpA – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Sep 13, 2018: Newron reports half-year 2018 results 30
Mar 01, 2018: Newron Announces 2017 Financial Results and Provides Outlook for 2018 32
Sep 14, 2017: Newron reports half-year 2017 results 35
Mar 02, 2017: Newron announces 2016 financial results and provides outlook for 2017 37
Corporate Communications 38
Apr 05, 2017: Eisai and Meiji to commercialise safinamide for Parkinson’s disease in Japan and Asia 38
Product News 39
10/25/2017: Newron Pharmaceuticals to Present at European Rett Syndrome Congress and Host Advisory Board Meeting 39
07/11/2017: XADAGO (Safinamide) Now Available in the U.S. for Parkinson’s Disease Patients 40
05/12/2017: Newron Receives EUR11.3m Milestone Payments for US Approval of Xadago (safinamide) 41
04/10/2017: Zambon Launches Xadago (Safinamide) In Portugal For Patients With Mid- To Late-Stage Parkinson’s Disease 42
03/21/2017: FDA approves drug to treat Parkinson’s disease 43
03/02/2017: Newron Provides Update on Sarizotan 44
03/02/2017: Newron Pharmaceuticals Provides Update on Xadago (safinamide) 45
02/08/2018: Newron Pharmaceuticals Announces Change in the Board of Directors 46
02/01/2018: Primary Endpoint Met In Phase II/III Clinical Study of Investigational Parkinson’s Disease Treatment Safinamide in Japan 47
Product Approvals 48
Jun 12, 2017: Zambon’s Xadago Rejects For Use Within NHS Scotland 48
Clinical Trials 49
Jun 13, 2018: Newron Provides Update on STARS Clinical Study with Sarizotan for the Treatment of Rett Syndrome 49
May 17, 2017: Newron Pharmaceuticals Announces Expansion of STARS Study to Include Patients Under 13 Years of Age 50
Other Significant Developments 51
Mar 27, 2018: Newron Pharmaceuticals Announces Shareholders Accepted All Motions at the AGM 2018 51
Dec 11, 2017: Newron Provides End of Year Corporate Update 52
Nov 07, 2017: Newron Pharmaceuticals Announces Advisory Board Recommendations and Rett Congress Findings 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Newron Pharmaceuticals SpA, Deals By Therapy Area, 2012 to YTD 2018 9
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Newron Pharma Enters Into Co-Development Agreement With Zambon 11
Newron Pharma Enters Into Licensing Agreement With Zambon For Safinamide 12
Newron Enters Into Licensing Agreement With Meiji Seika Pharma For Safinamide 14
Newron Pharma Raises USD27.8 Million in Private Placement of Shares 16
Newron Pharma to Raise USD26.7 Million in Private Placement of Shares 17
Newron Pharma to Raise USD5.3 Million in Private Placement of Shares 18
Newron Pharma to Raise USD25.6 Million in Private Placement of Shares 19
Newron Pharma to Raise Funds through Public Offering of Shares 21
Newron Pharma Announces Private Placement Of Shares For US$21 Million 22
Newron Pharma Completes Private Placement Of Shares For US$4.8 Million 24
Newron Pharma Completes Acquisition Of NeuroNova For US$12 Million 25
Newron Pharmaceuticals SpA, Key Competitors 27
Newron Pharmaceuticals SpA, Key Employees 28
Newron Pharmaceuticals SpA, Subsidiaries 29

List of Figures
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Newron Pharmaceuticals SpA (NWRN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • CHS Inc (CHSCP):企業の財務・戦略的SWOT分析
    CHS Inc (CHSCP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Xylem Inc (XYL):企業の財務・戦略的SWOT分析
    Xylem Inc (XYL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • M. A. Mortenson Co:戦略・SWOT・企業財務分析
    M. A. Mortenson Co - Strategy, SWOT and Corporate Finance Report Summary M. A. Mortenson Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • OBJ Ltd (OBJ):企業の財務・戦略的SWOT分析
    Summary OBJ Ltd (OBJ) is a developer of magnetic micro-array drug and ingredient delivery technologies. The company offers services such as drug or ingredient profiling in skin, laboratory facilities and capabilities, formulation development, product development, product optimisation, and pre-commer …
  • Clarins SA:企業の戦略・SWOT・財務情報
    Clarins SA - Strategy, SWOT and Corporate Finance Report Summary Clarins SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Future Plc (FUTR):企業の財務・戦略的SWOT分析
    Summary Future Plc (Future) is a media company that offers media and digital business solutions various customers. The company offers its services in various areas such as technology, creative, photography and design, games, advertising and film and music. It provides licensing and syndication, expo …
  • Wellcome Trust Sanger Institute-製薬・医療分野:企業M&A・提携分析
    Summary Wellcome Trust Sanger Institute (Sanger Institute), a subsidiary of Genome Research Ltd is a genomic discovery and research centre that carries out research and development in the areas of cellular and human genetics and infection genomics. It also provides postgraduate training on research …
  • Stingray Digital Group Inc.:企業のM&A・事業提携・投資動向
    Stingray Digital Group Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Stingray Digital Group Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • LIG Nex1 Co Ltd:企業の戦略・SWOT・財務分析
    LIG Nex1 Co Ltd - Strategy, SWOT and Corporate Finance Report Summary LIG Nex1 Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Bunge Ltd (BG):企業の財務・戦略的SWOT分析
    Bunge Ltd (BG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Tokio Marine Asia Pte. Ltd.
    Tokio Marine Asia Pte. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Tokio Marine Asia Pte. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Exonate Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Exonate Ltd (Exonate) is a biopharmaceutical company that discovers and develops small molecule drugs which modulates the alternative mRNA splicing for the treatment of unmet medical needs. The comany's alternative mRNA splicing is modulated in disease states that results in the pathological …
  • Asahi Group Holdings Ltd:企業のM&A・事業提携・投資動向
    Asahi Group Holdings Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Asahi Group Holdings Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Complexa Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Complexa Inc (Complexa) is a biopharmaceutical company that develops endogenous human cell signalling treatments for fibrosis and inflammation related diseases. The company’s lead product candidate products includes CXA-10 is an endogenous nitro fatty acid that modulates the human body’s mai …
  • Caribbean Utilities Company, Ltd.:企業の発電所・SWOT分析2018
    Caribbean Utilities Company, Ltd. - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on …
  • Kaneka Corp (4118):企業の財務・戦略的SWOT分析
    Kaneka Corp (4118) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Turkcell Iletisim Hizmetleri AS (TCELL):企業の財務・戦略的SWOT分析
    Turkcell Iletisim Hizmetleri AS (TCELL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Bourbon SA (GBB)-石油・ガス分野:企業M&A・提携分析
    Summary Bourbon SA (Bourbon) is a provider of marine and subsea services to the oil and gas industry. The company’s services consist of transport and supply of offshore material, floating production, storage and offloading (FPSO) support, anchor handling, towage and offshore positioning, assistance, …
  • AbbVie Inc (ABBV)-製薬・医療分野:企業M&A・提携分析
    Summary AbbVie Inc (AbbVie) is a research-based biopharmaceutical company that carries out the research, development, manufacture and commercialization of advanced therapies to treat complex and serious diseases. The company focuses on providing drugs in immunology, cancer, neuroscience and virology …
  • Trade Me Group Limited:企業の戦略・SWOT・財務情報
    Trade Me Group Limited - Strategy, SWOT and Corporate Finance Report Summary Trade Me Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆